As Vice President of Global Health at RTI International, Dr. Doris Rouse manages the application of diverse disciplines in research, pre-clinical and clinical development programs for new interventions to address global health needs.
Programs in her division address global health needs in the following areas:
She has extensive experience in forming public and private consortia. For example, she has contributed to the formation and activities of the Global Alliance for TB Drug Development (TB Alliance), an international public/private consortium to develop new drugs for tuberculosis. Dr. Rouse serves as the Principal Investigator on tuberculosis drug development contracts from the National Institutes of Health and the TB Alliance. She also leads a Bill & Melinda Gates Foundation grant entitled Venture Investment Technical Assistance (VITA), working with a venture capital firm and their portfolio companies to develop new products for global health. Dr. Rouse currently serves on the Global Health Advisory Committee for the University of North Carolina School of Public Health.
Previously, in her tenure as Director of the Center for Technology Applications at RTI, Dr. Rouse managed technology assessment, outlicensing, and technology sourcing projects for numerous government and corporate clients. Product areas addressed in these projects included medical diagnostics and therapeutics, medical treatment devices, assistive devices, software, and sensors. Dr. Rouse served on the national bioengineering advisory board for the Association for Retarded Citizens (now ARC) and chaired an American National Standards Institute committee for development of wheelchair safety and effectiveness standards. As a Peace Corps volunteer, she taught science in Liberia. Dr. Rouse has both a B.A. in Chemistry and a Ph.D. in Physiology and Pharmacology from Duke University.